Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2008

View Archived Issues

Shionogi-GlaxoSmithKline starts phase IIa study with GSK-1349572 in HIV patients

GSK's 5-HT6 receptor antagonist SB-742457 improves global function in mild-to-moderate AD

Tau aggregation inhibitor rember stops Alzheimer's disease progression

Novel potent O-GlcNAcase inhibitor blocks Tau phosphorylation in preclinical studies

Novel CDK-2 receptor inhibitor shows preliminary antitumor effects in mice

Recent patents describe novel therapeutic agents for asthma and other respiratory disorders

Novel anticancer agents disclosed in recent patent literature

Preliminary data shows phase III Cerepro trial meets primary endpoint

IDEA presents an update on the clinical development of Diractin for knee OA

Synairgen initiates enrollment in SG004 phase I clinical study of IFN-beta for asthma

Celator series C private financing to advance clinical development programs

Clavis Pharma amends clinical program for Elacyt

FDA accepts labeling regarding food in IntelGenx's and Cary's NDA for CPI-300

ImQuest receives SBIR grant from the NIAID to develop pyrimidinedione product in HIV

Cytochroma and Mitsubishi Tanabe sign a U.S. and Asian license agreement for CTA-018

AtheroGenics reports positive results from phase III ANDES trial in diabetes

Roche files European MAA for MabThera for chronic lymphocytic leukemia

Medicago presents a report on activities during the first 7 months of 2008

Orexo and ProStrakan extend licensing agreement for Rapinyl to include North America

New agents intended for use in treatment of anxiety, depression, etc., disclosed in recent patents

Sanofi pasteur begins shipping Fluzone influenza vaccine for the 2008-2009 season

PolyMedix completes USD 15 million registered equity financing

Genmab and GSK report positive results from phase III study of ofatumumab in CLL

Biota reports positive results from phase II clinical study of CS-8958 in influenza

FDA confirms that no additional trials required in Cadence's NDA for Acetavance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...